353 related articles for article (PubMed ID: 21109949)
1. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
Goc A; Al-Husein B; Kochuparambil ST; Liu J; Heston WW; Somanath PR
Int J Oncol; 2011 Jan; 38(1):267-77. PubMed ID: 21109949
[TBL] [Abstract][Full Text] [Related]
2. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
3. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
[TBL] [Abstract][Full Text] [Related]
4. PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro.
Toulany M; Dittmann K; Fehrenbacher B; Schaller M; Baumann M; Rodemann HP
DNA Repair (Amst); 2008 Oct; 7(10):1746-56. PubMed ID: 18678286
[TBL] [Abstract][Full Text] [Related]
5. High glucose regulates cyclin D1/E of human mesenchymal stem cells through TGF-beta1 expression via Ca2+/PKC/MAPKs and PI3K/Akt/mTOR signal pathways.
Ryu JM; Lee MY; Yun SP; Han HJ
J Cell Physiol; 2010 Jul; 224(1):59-70. PubMed ID: 20232305
[TBL] [Abstract][Full Text] [Related]
6. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
Bibollet-Bahena O; Almazan G
J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
8. γ-Enolase C-terminal peptide promotes cell survival and neurite outgrowth by activation of the PI3K/Akt and MAPK/ERK signalling pathways.
Hafner A; Obermajer N; Kos J
Biochem J; 2012 Apr; 443(2):439-50. PubMed ID: 22257123
[TBL] [Abstract][Full Text] [Related]
9. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
10. Thrombopoietin (TPO) induces c-myc expression through a PI3K- and MAPK-dependent pathway that is not mediated by Akt, PKCzeta or mTOR in TPO-dependent cell lines and primary megakaryocytes.
Chanprasert S; Geddis AE; Barroga C; Fox NE; Kaushansky K
Cell Signal; 2006 Aug; 18(8):1212-8. PubMed ID: 16380230
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways.
Kraus S; Levy G; Hanoch T; Naor Z; Seger R
Cancer Res; 2004 Aug; 64(16):5736-44. PubMed ID: 15313914
[TBL] [Abstract][Full Text] [Related]
12. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
13. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
14. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
15. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
[TBL] [Abstract][Full Text] [Related]
16. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation.
Borowiec AS; Hague F; Harir N; Guénin S; Guerineau F; Gouilleux F; Roudbaraki M; Lassoued K; Ouadid-Ahidouch H
J Cell Physiol; 2007 Sep; 212(3):690-701. PubMed ID: 17520698
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of fucosyltransferase IV promotes A431 cell proliferation through activating MAPK and PI3K/Akt signaling pathways.
Yang XS; Liu S; Liu YJ; Liu JW; Liu TJ; Wang XQ; Yan Q
J Cell Physiol; 2010 Nov; 225(2):612-9. PubMed ID: 20506505
[TBL] [Abstract][Full Text] [Related]
18. Essential role for G proteins in prostate cancer cell growth and signaling.
Kue PF; Daaka Y
J Urol; 2000 Dec; 164(6):2162-7. PubMed ID: 11061948
[TBL] [Abstract][Full Text] [Related]
19. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
20. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.
Kochuparambil ST; Al-Husein B; Goc A; Soliman S; Somanath PR
J Pharmacol Exp Ther; 2011 Feb; 336(2):496-505. PubMed ID: 21059805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
